Dune Medical Devices Ltd. Announces Appointment of Roger Blanchette as Chief Financial Officer
Published: Nov 23, 2011
"We are thrilled to have Roger join us at Dune as we continue our introduction of the MarginProbe System in Europe and prepare for widespread commercial introduction in the U.S. Roger's prior experience is an ideal match with Dune today, and considerably strengthens our management team as we approach several critical events in the growth of our company. I look forward to working closely with Roger as we build a strong and sustainable global business," said Dan Levangie, Dune Chief Executive Officer.
About Dune Medical Devices
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary cancer detection technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. The MarginProbe System is Dune's first commercial product.
About the MarginProbe System
The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer. The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, potentially saving a second procedure.
Dune Medical Devices is a privately held company financed by Apax Partners. It has offices in the U.S., Israel and Switzerland. For more information, please visit www.dunemedical.com
Dune Medical Devices
111 Speen Street
SOURCE Dune Medical Devices, Inc.